Bard 1808061 PowerPort iSP MRI Implantable Port w/ Attachable 8F Polyurethane Open-Ended Single-Lumen Venous Catheter Kit 1/EA

Bard 1808061 PowerPort iSP MRI Implantable Port w/ Attachable 8F Polyurethane Open-Ended Single-Lumen Venous Catheter Intermediate Kit 1/EA

• Model: 1808061
• Catheter Size: 8 French (8 Fr)

The PowerPort® ISP MRI Implantable Port with Attachable 8 Fr Polyurethane Open‑Ended Single‑Lumen Venous Catheter is a state‑of‑the‑art vascular access solution engineered for reliable long‑term therapy delivery. Designed for patients requiring frequent intravenous access — such as chemotherapy, IV antibiotics, parenteral nutrition, and blood sampling — this advanced port system combines patient comfort with clinical performance. Its MRI Conditional design allows safe imaging under specified conditions, helping clinicians confidently monitor therapy progress without compromising patient safety.

Constructed with a radiotranslucent port housing and a polyurethane catheter, the PowerPort ISP system delivers exceptional imaging clarity and durability. The 8 Fr single‑lumen catheter ensures efficient, uninterrupted infusions, while the attachable design allows for secure connection and streamlined implantation. Engineered with biocompatible materials and radiopaque features for precise visualization during placement and follow‑up imaging, this implantable port supports enhanced procedural outcomes and more predictable vascular access over time.

Clinicians and healthcare facilities trust the PowerPort ISP MRI Implantable Port for its combination of patient‑centric design and robust clinical performance. Lightweight and low profile, it promotes patient comfort and reduces cosmetic impact, while its reliable construction supports consistent access for dosing, sampling, and therapeutic regimens. Whether deployed in oncology centers, infusion suites, or acute care settings, this single‑lumen implantable port delivers dependable vascular access that supports both clinician workflow and patient quality of life throughout long‑term treatment courses.